hero image
Dana P. Goldman, PhD - USC School of Pharmacy. Los Angeles, CA, US

Dana P. Goldman, PhD Dana P. Goldman, PhD

Leonard D. Schaeffer Director's Chair, USC Schaeffer Center for Health Policy and Economics & Distinguished Professor of Public Policy, Pharmacy and Economics | USC School of Pharmacy

Los Angeles, CA, UNITED STATES

Dana Goldman is an expert in health care reform, managed care and drug costs.

Multimedia

Publications:

Documents:

Photos:

Schaeffer Center loading image loading image loading image

Videos:

Dr Dana Goldman Says Drug Pricing Is Being Viewed the Wrong Way Experts Explain: Dana Goldman on Drug Pricing

Audio:

Social Media

Biography

Dana P. Goldman is the Leonard D. Schaeffer Chair and a Distinguished Professor of Public Policy, Pharmacy, and Economics at the University of Southern California. He also directs the USC Schaeffer Center for Health Policy and Economics, a research hub for one of the nation’s premier health policy and management programs in the Sol Price School of Public Policy and USC School of Pharmacy. He is an elected member of the National Academy of Medicine and the National Academy of Social Insurance – two of his field’s highest honors. He is the author of more than 300 articles and book chapters, and his research has been published in leading medical, economic, health policy, and statistics journals. His research has been continuously funded by many public and private sources— including more than $50 million from the National Institutes of Health.

Professor Goldman has served as a formal health policy advisor to the Congressional Budget Office, Covered California, and the Fred Hutchinson Cancer Institute—as well as informally for many private companies and government officials. He serves on the editorial boards of Health Affairs and the American Journal of Managed Care and is founding editor of the Forum for Health Economics and Policy. His work has been featured in the New York Times, Wall Street Journal, Washington Post, The Economist, NBC Nightly News and other media. He is former director of ISPOR and ASHEcon. Dr. Goldman received his B.A. summa cum laude from Cornell University and a Ph.D. in Economics from Stanford University.

Areas of Expertise (6)

health technology assessment

Drug pricing

Health Care Reform

Health Policy and Economics

Managed Care

Formulary Design

Accomplishments (1)

USC Associates Award for Creativity in Research

2017 - Associates awards are “the highest honors the university faculty can bestow on its members for distinguished intellectual and artistic achievements.”

Education (2)

Stanford University: Ph.D., Economics

Cornell University: B.A.

Summa cum laude

Affiliations (2)

  • Elected member, National Academy of Medicine
  • Elected member, National Academy of Social Insurance

Selected Media Appearances (6)

Media

Op-eds, media appearances and commentary  

Dr. Goldman's work has been featured in the New York Times, Wall Street Journal, Forbes, Washington Post, Business Week, U.S. News and World Report, The Economist, NBC Nightly News, CNN, National Public Radio, and other media.

Opinion: This is a health-care plan both Republicans and Democrats should agree onq

MarketWatch  online

2019-08-06

The one area of agreement in the debate over health insurance is that too many Americans lack it — now 27 million and counting. The differences emerge over how to expand coverage and how to pay for it.

view more

Here's how we can control drug costs while spurring innovation

The Hill  online

2019-06-14

Health care is one of the most valuable services that Americans spend their money on, but it also can be the most expensive. Political pressure to do something is enormous. Given the partisan slow boat in Washington, states have started to move with willingness — especially with regard to prescription drugs. This is posing a huge challenge to a rational national policy.

view more

Opinion: Health Care's Killer App: Life Insurance

Wall Street Journal  print

2019-03-20

The industry could profit by helping policyholders pay for cancer treatments that prolong life.

view more

Opinion: The bigger message behind Amgen’s decision to slash cost of its Repatha cholesterol drug

MarketWatch  online

2018-10-29

Amgen has just announced a 60% cut in the price of its innovative anti-cholesterol medicine, Repatha. That is big news to people at risk for heart attacks and strokes, many of whom had been forgoing the treatment because of high out-of-pocket costs.

view more

Opinion: When we find a cure, price it like Netflix to ensure access

The Hill  online

2018-08-13

An essential lesson from the successful fight against AIDS is that early access to effective treatment can avoid long-term costs.

view more

Research Grants (5)

Roybal Center for Health Policy Simulation

National Institute on Aging 

2004-2019

Transforming Research and Clinical Knowledge in Traumatic Brain Injury II

NINDS 

2013-2018

Resource Center for Minority Aging Research

National Institutes of Health 

2012-2017

Technological Innovation in Health Care and the Long-Term Outlook

National Institutes of Health 

2014-2016

An Economic and Behavioral Evaluation of Medicare Part D

National Institute on Aging 

2011-2016

Selected Articles (6)

Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017 Value in Health

2019

The prices of newly approved cancer drugs have risen over the past decades. A key policy question is whether the clinical gains offered by these drugs in treating specific cancer indications justify the price increases.

view more

Insulin Access and Affordability Working Group: Conclusions and Recommendations American Diabetes Association

2018

There are more than 30 million Americans with diabetes, a disease that costs the U.S. more than $327 billion per year (1,2). Achieving glycemic control and controlling cardiovascular risk factors have been conclusively shown to reduce diabetes complications, comorbidities, and mortality.

view more

Encouraging New Uses for Old Drugs JAMA Network

2017

US Food and Drug Administration (FDA) approval of a new drug typically coincides with a period of patent protection, during which the manufacturer will often apply for additional indications to expand the market for the product. For example, the tyrosine kinase inhibitor imatinib (Gleevec; Novartis) was originally approved to treat Philadelphia chromosome–positive chronic myelogenous leukemia, but has since been approved for treatment of other cancers.

view more

Prescription Drug Cost Sharing JAMA Network

2017

Prescription drugs are instrumental to managing and preventing chronic disease. Recent changes in US prescription drug cost sharing could affect access to them.

view more

Substantial Health And Economic Returns From Delayed Aging May Warrant A New Focus For Medical Research Health Affairs

2013

Recent scientific advances suggest that slowing the aging process (senescence) is now a realistic goal. Yet most medical research remains focused on combating individual diseases. Using the Future Elderly Model—a microsimulation of the future health and spending of older Americans—we compared optimistic “disease specific” scenarios with a hypothetical “delayed aging” scenario in terms of the scenarios’ impact on longevity, disability, and major entitlement program costs.

view more

Drug Licenses: A New Model For Pharmaceutical Pricing Health Affairs

2008

High drug prices are a major barrier to patients’ access to drugs and compliance with treatment. Yet low drug prices are often argued to provide inadequate incentives for innovation.

view more